NCT03825731 - A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

September 16, 2019

Study Completion Date

September 16, 2019

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

GC022

GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10\^5 to 1×10\^7 CAR+T/Kg.

Trial Locations (1)

065200

RECRUITING

Hebei Yanda Ludaopei Hospital, Sanhe